Analysis for different expressed of circrnas and urine proteomics in urine exosomes of patients with mild to moderate type 2 diabetic nephropathy to be treated by Dapagliflozin

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026681

Enrollment

Unknown

Registered

2019-10-18

Start date

2019-11-01

Completion date

Unknown

Last updated

2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Interventions

Treated group:Dapagliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Be able to understand the purpose of clinical trials, participate voluntarily and sign informed consent; 2. Aged 18-70 years old male and female; 3. Patients with type 2 diabetes were definitely diagnosed according to WHO diagnostic criteria; 4. Urine routine test suggested urine protein (1+-2+), or three urine biochemical tests suggested urine microalbumin/urine creatinine 31-300mg/g;Diabetic retinopathy; 5. Regular application of hypoglycemic drugs, combined with diabetic diet and exercise to control blood glucose;Stable blood glucose; 6. Be able to follow the insulin regimen and diabetes diet determined by the researcher.

Exclusion criteria

Exclusion criteria: 1. EGFR normal value is 3 times, or severe liver diseases accompanied by uncompensated cirrhosis, jaundice, ascites or hemorrhagic varicose vessels; 3. Uncontrolled hypoglycemia or hyperglycemia with large variability of blood glucose, which is considered unsuitable for participants; 4. Those with severe retinopathy or who cannot be examined for retinopathy; 5. Had received or was receiving systemic hormone and immunosuppressive therapy within 3 months before screening; 6. Grade 3 hypertension (extremely high risk group); 7. Serious systemic diseases (cardiovascular system, respiratory system, digestive system, nervous system, urogenital system, blood system), malignant tumors or mental diseases; 8. History of drug or alcohol abuse or dependence; 9. Poor compliance, inability to complete the trial as required, or other reasons not suitable for participation (as judged by the study physician).

Design outcomes

Primary

Measure	Time frame
Urinary exosome circrnas;urine protein;	—

Secondary

Measure	Time frame
waistline;weight;High;blood biochemistry indexes;Blood routine tests;urine routine tests;	—

Countries

China

Contacts

Public ContactMaoguang Yang

The Second Hospital of Jilin University

154633695@qq.com+86 13664431161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026